Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

Tardive dyskinesia shares features with other movement disorders, such as Tourette syndrome and drug-induced Parkinsonism. But a diagnostic evaluation can reveal which condition is causing the ...

Accurate and early diagnosis of tardive dyskinesia (TD), a serious movement disorder typically caused by exposure to antipsychotic medications, is imperative for long-term management. "Keeping an eye ...

Tardive dyskinesia is not typically reversible, but on rare occasions, it can be if caught early and treated immediately. Tardive dyskinesia (TD) is a medication-induced movement disorder involving ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients with tardive dyskinesia were adherent to deutetrabenazine vs. valbenazine.

So one of the trials that I'm interested in watching is an extension trial of the IMPACT-TD registry that's currently going on and being done by Teva Pharmaceuticals, who are the manufacturers of ...

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental ...

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), today announced new patient- and ...